CATX
AMEX · Biotechnology
Perspective Therapeutics Inc
$2.95
-0.03 (-1.01%)
Financial Highlights (FY 2026)
Revenue
1.37M
Net Income
-159,333,941
Gross Margin
23.1%
Profit Margin
-11,665.3%
Rev Growth
-37.1%
D/E Ratio
0.01
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 23.1% | 23.1% | 30.3% | 30.3% |
| Operating Margin | -12,846.6% | -11,562.0% | -17.7% | -15.3% |
| Profit Margin | -11,665.3% | -11,082.0% | -15.6% | -13.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.37M | 2.18M | 70.28M | 78.45M |
| Gross Profit | 316.1K | 502.5K | 21.26M | 23.73M |
| Operating Income | -175,812,795 | -251,520,450 | -12,462,432 | -12,042,185 |
| Net Income | -159,333,941 | -227,945,552 | -10,926,196 | -10,214,084 |
| Gross Margin | 23.1% | 23.1% | 30.3% | 30.3% |
| Operating Margin | -12,846.6% | -11,562.0% | -17.7% | -15.3% |
| Profit Margin | -11,665.3% | -11,082.0% | -15.6% | -13.0% |
| Rev Growth | -37.1% | -37.1% | +8.8% | +21.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.30M | 1.30M | 184.55M | 188.23M |
| Total Equity | 166.92M | 166.92M | 242.97M | 259.56M |
| D/E Ratio | 0.01 | 0.01 | 0.76 | 0.73 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -170,442,040 | -257,383,465 | -18,107,687 | -17,982,441 |
| Free Cash Flow | — | — | -6,087,830 | -8,175,378 |